One of the strongest indications for the use of mood stabilizers is bipolar disorder, a mood disorder comprised of two types. Bipolar I disorder is defined by at least one lifetime manic episode, while bipolar II disorder is defined by at least one past or present hypomanic episode with at least one past or present major depressive episode. The manic and depressive characteristics of bipolar disorder require the use of particular mood stabilizers that can cater to the patient’s individual needs.
Different agents belonging to the mood stabilizer class of medications have strengths and weaknesses owing to their indications, contraindications, and their protocol for follow-up. Clinicians are encouraged to choose a mood stabilizer keeping these different factors in mind so that patient outcomes may improve by an informed choice made in the pharmacological management of patients with bipolar disorder.
Non-FDA Approved Indications:
Although there is still more to discover about the particulars of lithium, valproic acid/divalproex, and carbamazepine, a suggested common mechanism for their mood-stabilizing abilities is inhibition of the inositol uptake process, resulting in inositol depletion. In this proposed mechanism, the myo-inositol monophosphate transporter and its respective mRNA become downregulated by the above mentioned three major mood-stabilizing agents. The mechanisms of individual key mood-stabilizing agents is discussed in further detail below:
Lithium: Lithium’s mechanism of action is still under investigation for its neuroprotective benefits. However, the currently proposed inositol depletion hypothesis explains that lithium downregulates polyphosphoinositide signaling by acting as an uncompetitive inhibitor of inositol monophosphatase and inositol polyphosphate 1-phosphatase. Thus, lithium inhibits neuronal excitation, leading to its benefits as a mood stabilizer.
Divalproex: Divalproex—or valproate, valproic acid—is an anticonvulsant drug that functions as a mood stabilizer and antiepileptic agent by enhancing the inhibitory effect of gamma aminobutyric-acid (GABA). This therapy reduces repetitive neuronal firing and can reduce inhibition and excitation within neuronal networks.
Carbamazepine: Carbamazepine follows suit with the other mood-stabilizing agents mentioned, with an additional specific mechanism of action identified wherein cAMP accumulation becomes inhibited, resulting in the downregulation of the inositol transporter.
Lamotrigine: Lamotrigine, like valproate, is an anticonvulsant. Its mechanism of action involves reducing only the frequency (and not amplitude) of excitatory postsynaptic currents in the CNS, causing a decrease in glutamate release while causing a concomitant increase in frequency and amplitude of inhibitory postsynaptic currents, which enhances GABA release. Therefore, lamotrigine causes opposite effects on glutamate and GABA transmission, downregulating glutamate release, and increasing GABA release.
Lithium: Lithium may cause tremor, weight gain, or lead to hypothyroidism. Due to lithium's excretion via the kidneys, adverse effects manifest in the form of nephrogenic diabetes insipidus and, more rarely, chronic tubulointerstitial nephritis. About 20 to 40% of patients taking lithium chronically develop polyuria and polydipsia. Fortunately, the nephrogenic diabetes insipidus that occurs as a result of lithium therapy is managed similarly with thiazide diuretics, NSAIDs, and a low salt diet.
Valproic Acid: Valproic acid's adverse effects include weight gain and GI disturbances such as nausea and vomiting, as well as alopecia, tremor, and easy bruising, most probably owing to its effects on coagulation. About 5 to 10% of patients placed on a long-term valproic acid regimen develop transaminitis, although a substantial amount of cases resolve on their own without necessity for discontinuing the regimen. Other more serious forms of valproic acid toxicity include encephalopathy secondary to hyperammonemia, hepatotoxicity, and acute pancreatitis. The risk of teratogenicity (especially when using valproic acid as monotherapy) is a discussion topic below.
Carbamazepine: Carbamazepine has both systemic and neurological side effects. The systemic adverse effects are dual-faceted, including GI and integumentary systems. GI upset is characterized by nausea, vomiting, diarrhea, and hyponatremia. The integumentary issues characteristically are pruritis and rash. The neurologic defects associated with carbamazepine therapy include headache, dizziness, vision changes (blurry or diplopia), lethargy, and drowsiness.
Lamotrigine: Lamotrigine therapy has a similar adverse effect profile as carbamazepine in that it involves rash and nausea as prominent side effects. Neurologic side effects include diplopia, dizziness, and tremor.
The adverse effects of the different mood stabilizers appear in further detail under the 'Contraindications' and 'Toxicity' headings below.
Prescribers need to pay attention to the metabolism and processing of the mood-stabilizing agents as their accumulation in the body can lead to their toxicities and adverse effects.
Lithium clearance is through the kidneys. As renal function decreases with age, prescribers should exercise caution in patients over the age of 60 years old and those with renal failure. Additionally, lithium should be avoided in those with cardiac failure due to its ability to alter the functioning of the sodium-potassium transporter, which can worsen arrhythmias. Lithium should be discontinued within the first three months of pregnancy, and the decision to resume therapy is up to the patient’s psychiatrist and whether the benefits of treatment outweigh the risks. There is some evidence that lithium can cause facial malformations in infants born to mothers on lithium therapy. Lithium teratogenicity is rare compared to other mood stabilizers mentioned in this article: valproic acid, carbamazepine, and lamotrigine.
Valproic acid should be avoided in pregnancy and harbors a serious adverse effect of fatal hepatotoxicity. It may also cause pancreatitis, SIADH, hyponatremia, headache, nausea, vomiting, weight gain, diarrhea, and abdominal pain.
Lamotrigine and carbamazepine are both capable of causing Stevens-Johnson syndrome; therefore, patients should learn to monitor themselves for any skin changes or new rashes after initiation of a mood stabilizer regimen with either of these drugs.
Before initiating lithium therapy, the clinician should perform a thorough physical exam that includes palpation of the thyroid gland and obtain creatinine, blood urea nitrogen, and thyroid function test, including T3, T4, and TSH levels along with a urinalysis and electrocardiogram.
Due to valproic acid’s ability to cause fatal hepatotoxicity, LFTs are necessary before initiating therapy to establish a baseline for the comparison of LFTs can for follow-up monitoring.
Treatment with the ion lithium affects multiple organ systems, most notably the central nervous system and the GI system, causing tremors, twitching, drowsiness, a feeling of sluggishness, vomiting, diarrhea, and loss of appetite. Most minor symptoms of toxicity are treatable by adjustment of the medication dose.
Lithium's toxicity profile is additionally remarkable for a decreased ability to concentrate urine, hypothyroidism, weight gain, and hyperparathyroidism. The use of lithium during pregnancy is not without risks, so an assessment of the benefits vs. risks is a requirement before discontinuing lithium during pregnancy. Hyperparathyroidism is a consistent finding associated with lithium use, so calcium levels should be checked before and monitored throughout the duration of pharmacotherapy. It bears mention that elderly patients are more vulnerable to lithium toxicity. In the event of lithium toxicity, dialysis can be performed and is the treatment of choice, owing to lithium's low molecular weight. Lithium clearance should be maximized in hypovolemic patients by normalizing sodium and water in patients with low-volume status.
Valproic acid toxicity is manifested most commonly as central nervous system depression and potential cerebral edema that can lead to coma and respiratory depression. These manifestations can occur alongside pancreatitis and hyperammonemia. The healthcare team needs to recognize toxicity as management requires a focus on maintaining the airway and supportive care.
Mood stabilizers represent a class of medications that can be expertly used in treatment regimens for bipolar mania and bipolar depression when used and managed correctly. The evaluation of specific mood-stabilizing agents must be tailored to each individual patient’s diagnosis and needs; this is where a team-based approach to pharmacologic management of bipolar disorder is well-deserved. The fact that the common medications included in this class have significant drug-drug interactions merits close scrutiny. Therefore, the patient’s physician should always confer with a pharmacist to decide which agent would perform best, given the patient’s current needs.
Aside from the initial council that is necessary before initiating a mood stabilizer regimen, the patient will need to follow-up regularly for monitoring. This will ensure that the agent is both functional and efficacious for the patient and not causing any untoward side effects or toxicities. In this way, clinicians and their teams of vital nursing and aid staff can keep a close watch on patients to ensure that the drugs they are taking are still working in their favor.
Overall, everyone on the healthcare team: physicians, nurses, and aids can all benefit from educating themselves on the distinguishing characteristics of the different major mood stabilizers. In regards to the receiving and admitting process of patients, medical staff should be knowledgeable about the various agents that their patients might be on, for it could be a reason or, at the very least, a related etiology as to their hospital or clinic visit in the first place. A more widespread knowledge about these agents would be beneficial to have or learn from any hospital standpoint.
|||McCormick U,Murray B,McNew B, Diagnosis and treatment of patients with bipolar disorder: A review for advanced practice nurses. Journal of the American Association of Nurse Practitioners. 2015 Sep; [PubMed PMID: 26172568]|
|||Lubrich B,van Calker D, Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1999 Oct; [PubMed PMID: 10481836]|
|||Berridge MJ,Downes CP,Hanley MR, Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989 Nov 3; [PubMed PMID: 2553271]|
|||Kerr F,Bjedov I,Sofola-Adesakin O, Molecular Mechanisms of Lithium Action: Switching the Light on Multiple Targets for Dementia Using Animal Models. Frontiers in molecular neuroscience. 2018; [PubMed PMID: 30210290]|
|||Löscher W, Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS drugs. 2002; [PubMed PMID: 12269861]|
|||Faingold CL,Browning RA, Mechanisms of anticonvulsant drug action. II. Drugs primarily used for absence epilepsy. European journal of pediatrics. 1987 Jan; [PubMed PMID: 3107994]|
|||Chen G,Pan B,Hawver DB,Wright CB,Potter WZ,Manji HK, Attenuation of cyclic AMP production by carbamazepine. Journal of neurochemistry. 1996 Nov; [PubMed PMID: 8863517]|
|||Cunningham MO,Jones RS, The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology. 2000 Aug 23; [PubMed PMID: 10963757]|
|||Brown WT, The use of lithium carbonate in the treatment of mood disorders. Canadian Medical Association journal. 1973 Mar 17; [PubMed PMID: 4570682]|
|||Zhu MM,Li HL,Shi LH,Chen XP,Luo J,Zhang ZL, The pharmacogenomics of valproic acid. Journal of human genetics. 2017 Dec; [PubMed PMID: 28878340]|
|||Musetti L,Tundo A,Benedetti A,Massimetti G,Cambiali E,Pergentini I,Del Grande C,Dell'Osso L, Lithium, valproate, and carbamazepine prescribing patterns for long-term treatment of bipolar I and II disorders: A prospective study. Human psychopharmacology. 2018 Nov; [PubMed PMID: 30311959]|
|||Mitchell PB, Bipolar disorder. Australian family physician. 2013 Sep; [PubMed PMID: 24024220]|
|||Prabhavalkar KS,Poovanpallil NB,Bhatt LK, Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Frontiers in pharmacology. 2015; [PubMed PMID: 26557090]|
|||McKnight RF,Adida M,Budge K,Stockton S,Goodwin GM,Geddes JR, Lithium toxicity profile: a systematic review and meta-analysis. Lancet (London, England). 2012 Feb 25 [PubMed PMID: 22265699]|
|||Sztajnkrycer MD, Valproic acid toxicity: overview and management. Journal of toxicology. Clinical toxicology. 2002 [PubMed PMID: 12475192]|